Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables - Other (2016 - 2018)

Historic Receivables - Other for Adma Biologics (ADMA) over the last 3 years, with Q4 2018 value amounting to $961145.0.

  • Adma Biologics' Receivables - Other fell 2284.16% to $961145.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $961145.0, marking a year-over-year decrease of 2284.16%. This contributed to the annual value of $961145.0 for FY2018, which is 2284.16% down from last year.
  • Latest data reveals that Adma Biologics reported Receivables - Other of $961145.0 as of Q4 2018, which was down 2284.16% from $1.0 million recorded in Q3 2018.
  • In the past 5 years, Adma Biologics' Receivables - Other ranged from a high of $1.2 million in Q4 2017 and a low of $726409.0 during Q1 2018
  • In the last 3 years, Adma Biologics' Receivables - Other had a median value of $987823.0 in 2016 and averaged $1.0 million.
  • In the last 5 years, Adma Biologics' Receivables - Other skyrocketed by 2846.34% in 2017 and then crashed by 2284.16% in 2018.
  • Adma Biologics' Receivables - Other (Quarter) stood at $969675.0 in 2016, then grew by 28.46% to $1.2 million in 2017, then decreased by 22.84% to $961145.0 in 2018.
  • Its Receivables - Other stands at $961145.0 for Q4 2018, versus $1.0 million for Q3 2018 and $1.0 million for Q2 2018.